Ranbaxy's Discovery Unit To Move Into Daiichi Sankyo's Global R&D Structure To Create New Drugs Faster
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Keeping with the "hybrid business model" that it envisioned in taking over India's largest drug maker Ranbaxy in June 2008, Daiichi Sankyo has announced that the New Drug Discovery Research unit of the Indian firm will be transferred to its global R&D structure. The transaction has been approved by India's Department of Scientific and Industrial Research
You may also be interested in...
Ranbaxy's Loss Is Dr. Reddy's Gain As Merck Shifts R&D Project For Anti-infectives
MUMBAI - New Jersey-headquartered pharma giant Merck and Daiichi Sankyo-controlled Ranbaxy have mutually agreed to terminate their five-year discovery research collaboration signed in May 2008. The two allies were to discover and engage in clinical development of new products in the field of anti-infectives, mainly anti-fungal and anti-bacterial drug candidates
Ranbaxy's Loss Is Dr. Reddy's Gain As Merck Shifts R&D Project For Anti-infectives
MUMBAI - New Jersey-headquartered pharma giant Merck and Daiichi Sankyo-controlled Ranbaxy have mutually agreed to terminate their five-year discovery research collaboration signed in May 2008. The two allies were to discover and engage in clinical development of new products in the field of anti-infectives, mainly anti-fungal and anti-bacterial drug candidates
"We Know We Will Emerge Stronger In The U.S.," Says Ranbaxy CEO Atul Sobti: An Interview With PharmAsia News (Part 2 of 2)
Japan's third-largest drug maker, Daiichi Sankyo, acquired a 64- percent stake in India's most internationally known pharmaceutical brand - Ranbaxy - last June. The deal between an emerging innovator and an established generics drug maker surprised many, but was seen as a transformational one with a goal to expand reach and enhance cost efficiencies. Daiichi Sankyo was criticized later as concerns surfaced regarding Ranbaxy's manufacturing standards at two of its U.S.FDA-approved sites in India. After a complete management overhaul that saw Ranbaxy's promoter exiting the company, Daiichi Sankyo made Atul Sobti the CEO and managing director. In arguably the most in-depth interview after taking over the reins of Ranbaxy, Sobti, who has worked previously with companies like Hero Honda, opened up to PharmAsia News' India bureau on issues spanning U.S. FDA's actions to rebuilding Ranbaxy's reputation and opportunities in Europe, Africa, Japan and India.